Biocon aims to achieve $1 billion revenues in three years

21 Sep 2011 Evaluate

India’s largest listed biotechnology firm, Biocon is targeting to achieve $1 billion revenues in upcoming three years. The company sees itself among the top 10 global biotechnological companies in the world. Its major emphasis is on the chronic diseases. The main emphasis is on diabetes, cancer and auto immune diseases. The company is also planning to list Syngene, its research services unit within the period of next 18 months. Syngene is India’s leading contract organization offering integrated drug and development service with capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, customs synthetics, process R&D and formulation development for small and large molecules.

Last year the company had forayed into Malaysia and is in the process of setting up a bio manufacturing and R&D facility at Bio-Xcell, a biotechnology park and ecosystem in Iskandar Malaysia, Johor with an investment of about Rs 715 crore in the first phase.

Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies. The drug major also produces mycophenolate mofetil, sirolimus and tacrolimus.

Biocon Share Price

339.75 3.75 (1.12%)
10-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1510.00
Dr. Reddys Lab 6089.30
Cipla 1533.80
Zydus Lifesciences 1082.55
Lupin 1630.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.